The information in these press releases is accurate only as of the date of the particular press release. Theravance does not update press releases once they have been made public. Press releases may contain forward-looking statements and future events or actual results could differ materially from those projected in the forward-looking statements.

All Releases
View Summary Theravance to Present at the Cowen and Company 32nd Annual Health Care Conference
Feb 22, 2012 		PDF 10.5 KB Add to Briefcase
  Theravance Reports Fourth Quarter and Full Year 2011 Financial Results
Feb 9, 2012 		PDF 77.7 KB Add to Briefcase
  Theravance to Present at Investor Conferences in February 2012
Feb 1, 2012 		PDF 26.6 KB Add to Briefcase
  Theravance to Report Fourth Quarter and Full Year 2011 Financial Results on February 9, 2012
Jan 26, 2012 		PDF 20.9 KB Add to Briefcase
  GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily RelovairTM* in COPD and asthma
Jan 9, 2012 		PDF 131.7 KB Add to Briefcase
  Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV® (telavancin) for Injection
Jan 6, 2012 		PDF 81.6 KB Add to Briefcase
  Theravance to Present at the 30th Annual J.P. Morgan Healthcare Conference
Dec 28, 2011 		PDF 25.2 KB Add to Briefcase
  Theravance Announces Initiation of Phase 2 Study with Its MARIN Compound, TD-9855, for the Treatment of ADHD
Dec 12, 2011 		PDF 86.7 KB Add to Briefcase
  Theravance Announces Positive Results from a Phase 2a Study of its LAMA Candidate, TD-4208, for the Treatment of COPD
Nov 14, 2011 		PDF 132.6 KB Add to Briefcase
  Theravance to Present at Investor Conferences in November 2011
Nov 1, 2011 		PDF 26.6 KB Add to Briefcase
  Theravance Reports Third Quarter 2011 Financial Results
Oct 27, 2011 		PDF 81.1 KB Add to Briefcase
  Theravance Announces Presentation of GSK Phase 2 Data for LAMA (GSK573719) at CHEST 2011
Oct 19, 2011 		PDF 18.7 KB Add to Briefcase
  Theravance to Report Third Quarter 2011 Financial Results on October 27, 2011
Oct 13, 2011 		PDF 20.8 KB Add to Briefcase
  Astellas and Theravance Announce European Marketing Authorization for VIBATIV( R ) for Nosocomial Pneumonia Caused by MRSA
Sep 15, 2011 		PDF 84.6 KB Add to Briefcase
  Theravance to Present at Investor Conferences in September 2011
Aug 24, 2011 		PDF 19.7 KB Add to Briefcase
  Theravance Reports Second Quarter 2011 Financial Results
Jul 28, 2011 		PDF 79.2 KB Add to Briefcase
  Theravance to Report Second Quarter 2011 Financial Results on July 28, 2011
Jul 14, 2011 		PDF 20.9 KB Add to Briefcase
  GSK and Theravance announce results of two pivotal Phase III studies for RelovairTM in COPD
Jun 2, 2011 		PDF 116.5 KB Add to Briefcase
  Theravance to Present at Investor Conferences in June 2011
May 24, 2011 		PDF 25.3 KB Add to Briefcase
  Astellas and Theravance Receive Positive Opinion from CHMP for European Approval of VIBATIV( TM ) for Nosocomial Pneumonia Caused by MRSA
May 20, 2011 		PDF 99.5 KB Add to Briefcase
Showing 1-20 of 98 Page: 1 2 3 4 5  Next 20
Add to Briefcase = add release to Briefcase
Shareholder Tools
Search
Investor Relations
Close Video
Close Window
Close Window
Form content here please :)